Hematological Malignancies Clinical Trials

5 recruiting

Frequently Asked Questions

Common questions about Hematological Malignancies clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting
Phase 2

A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma

Hematological Malignancies
Janssen Research & Development, LLC510 enrolled77 locationsNCT04634552
Recruiting

Dynamic Individualized Risk Profiling of Patients With Relapsed/Refractory Lymphoid Malignancies and CD19-CAR T Cell Therapy (INTeRCePT 2.0)

LymphomaLymphoid Hematological Malignancies
University of Zurich50 enrolled1 locationNCT07472972
Recruiting

Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome

Smoldering Multiple MyelomaMyelodysplastic SyndromesWaldenstrom Macroglobulinemia+5 more
Dana-Farber Cancer Institute10,000 enrolled7 locationsNCT02269592
Recruiting
Not Applicable

APA and Relaxation by Biofeedback in Patients With Haematological Malignancy Admitted in ICU

AnxietyHematological MalignanciesRelaxation+1 more
Centre Hospitalier Régional Metz-Thionville90 enrolled1 locationNCT05475600
Recruiting

Drug Response Profiling (DRP) Registry Zurich for Hematological Malignancies

Hematological Malignancies
University Children's Hospital, Zurich1,000 enrolled1 locationNCT06550102
Recruiting
Phase 1Phase 2

Safety and Efficacy of SMART101 in Adult Patients With Hematological Malignancies After Haploidentical HSCT With Post-transplant Cyclophosphamide

Hematological Malignancies
Smart Immune SAS40 enrolled4 locationsNCT05768035
Recruiting
Phase 1

Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies

LymphomaLeukemiaMyeloma+1 more
The Affiliated People's Hospital of Ningbo University10 enrolled1 locationNCT05528887